ABIVAX Société Anonyme Yönetim

Yönetim kriter kontrolleri 2/4

ABIVAX Société Anonyme CEO'su Marc M. de Garidel, May2023 tarihinde atandı, in görev süresi 1.5 yıldır. in toplam yıllık tazminatı € 793.97K olup, şirket hissesi ve opsiyonları dahil olmak üzere 45.3% maaş ve 54.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.06% ine doğrudan sahiptir ve bu hisseler € 311.28K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 3.3 yıldır.

Anahtar bilgiler

Marc M. de Garidel

İcra Kurulu Başkanı

€794.0k

Toplam tazminat

CEO maaş yüzdesi	45.3%
CEO görev süresi	1.5yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Marc M. de Garidel'un ücretlendirmesi ABIVAX Société Anonyme'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€177m
Mar 31 2024	n/a	n/a	-€163m
Dec 31 2023	€794k	€359k	-€148m

Tazminat ve Piyasa: Marc M. 'ın toplam tazminatı ($USD 833.30K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.03M ).

Tazminat ve Kazançlar: Marc M. şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Marc M. de Garidel (66 yo)

1.5yrs

Görev süresi

€793,971

Tazminat

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He serves as CEO at ABIVAX Société Anonyme since May 5, 2023 amd serves as its Director. He had been its Interim Chair...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marc M. de Garidel	CEO & Director	1.5yrs	€793.97k	0.060% € 311.3k
Philippe Pouletty	Founder & Director	no data	€35.00k	0.43% € 2.2m
Didier Blondel	EVP, CFO & Board Secretary	7.8yrs	Veri yok	0.00059% € 3.0k
Didier Scherrer	Chief Scientific Officer	1.3yrs	Veri yok	0.057% € 291.9k
Patrick Malloy	Senior Vice President of Investor Relations	1.3yrs	Veri yok	Veri yok
Ida Hatoum	Chief People & Compliance Officer	1.4yrs	Veri yok	Veri yok
Pierre Courteille	Chief Business Officer	no data	Veri yok	0% € 0
Jerome Denis	Executive Vice President of Process Development & Manufacturing	1.2yrs	Veri yok	Veri yok
Ana Sharma	VP & Global Head of Quality	less than a year	Veri yok	Veri yok
Hema Keshava	Senior Vice President of Finance	no data	Veri yok	Veri yok
Chris Rabbat	VP & Global Head of Medical Affairs	no data	Veri yok	Veri yok
Kevin Shan	VP & Global Head of Biometrics	no data	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: 2X1 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marc M. de Garidel	CEO & Director	1.5yrs	€793.97k	0.060% € 311.3k
Philippe Pouletty	Founder & Director	10.9yrs	€35.00k	0.43% € 2.2m
Sylvie Gregoire	Chair of the Board	less than a year	Veri yok	Veri yok
Christian Trepo	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Lawrence Stanberry	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Troy Ignelzi	Independent Director	1.3yrs	€44.33k	Veri yok
Christoph Huber	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Claude Bertrand	Member of Scientific Advisory Board	5.1yrs	€4.94k	Veri yok
Luc Teyton	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
June Lee	Independent Director	1.3yrs	€35.24k	Veri yok
Corinna Bonsen-Thomas	Independent Non-Executive Director	7.4yrs	€135.16k	0% € 0
Ian McGowan	Chairman of Scientific Advisory Board	6.4yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2X1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

ABIVAX Société Anonyme Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

New major risk - Share price stability

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

New major risk - Revenue and earnings growth

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

No longer forecast to breakeven

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

No longer forecast to breakeven

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Insufficient new directors

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Forecast breakeven date moved forward to 2022

Insufficient new directors

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

No longer forecast to breakeven

Forecast to breakeven in 2021

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

New 90-day low: €20.80

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €29.40

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

New 90-day high: €21.45

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

New 90-day low: €17.24

First half earnings released

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low - €18.50

New 90-day low - €19.00

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş